The Holy Shrine of Imam Hussain has announced the launch of practical steps to transfer advanced technologies for manufacturing highly complex therapeutic treatments to Iraq, in cooperation with the U.S. Food and Drug Administration (FDA).

Dr. Haider Al-Abadi, Head of the Health and Medical Education Authority, stated that “the Health and Medical Education Authority of the Holy Shrine of Imam Hussain has signed the first agreement to bring advanced technologies for manufacturing highly complex therapies to Iraq—technologies that will receive FDA certification.”

He explained that this step establishes the foundation for a major project that will elevate Iraq to the level of countries that produce highly purified therapies and earn the trust of leading global institutions such as the FDA.

Al-Abadi added that these efforts form an essential phase of a broader project aimed at directly supporting cancer patients.

He continued, “The core concept of this initiative is to establish a modern industrial city within Iraq dedicated to the manufacturing of highly complex therapies through three major pharmaceutical companies, following the initial approval of the Iraqi government.”

He emphasized that this achievement marks a historic and unprecedented milestone for Iraq, positioning the country among those capable of producing such advanced therapies rather than relying solely on imports.

This initiative is part of a comprehensive national vision to reduce dependence on imported medications and support patients—especially those with cancer—by establishing a pharmaceutical production system in Iraq that meets international standards.